Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 321

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Open access
Ardini, Elena, Menichincheri, Maria, Banfi, Patrizia, Bosotti, Roberta, De Ponti, Cristina, Pulci, Romana, Ballinari, Dario, Ciomei, Marina, Texido, Gemma, Degrassi, Anna, Avanzi, Nilla, Amboldi, Nadia, Saccardo, Maria Beatrice, Casero, Daniele, Orsini, Paolo, Bandiera, Tiziano, Mologni, Luca, Anderson, David, Wei, Ge, Harris, Jason, Vernier, Jean-Michel, Li, Gang, Felder, Eduard, Donati, Daniele, Isacchi, Antonella, Pesenti, Enrico, Magnaghi, Paola, Galvani, Arturo·2016·Molecular Cancer Therapeutics

Abstract

Activated ALK and ROS1 tyrosine kinases, resulting from chromosomal rearrangements, occur in a subset of non–small cell lung cancers (NSCLC) as well as other tumor types and their oncogenic relevance as actionable targets has been demonstrated by the efficacy of selective kinase inhibitors such as crizotinib, ceritinib, and alectinib. More recently, low-frequency rearrangements of TRK kinases have been described in NSCLC, colorectal carcinoma, glioblastoma, and Spitzoid melanoma. Entrectinib, whose discovery and preclinical characterization are reported herein, is a novel, potent inhibitor of ALK, ROS1, and, importantly, of TRK family kinases, which shows promise for therapy of tumors bearing oncogenic forms of these proteins. Proliferation profiling against over 200 human tumor cell lines revealed that entrectinib is exquisitely potent in vitro against lines that are dependent on the drug's pharmacologic targets. Oral administration of entrectinib to tumor-bearing mice induced regression in relevant human xenograft tumors, including the TRKA-dependent colorectal carcinoma KM12, ROS1-driven tumors, and several ALK-dependent models of different tissue origins, including a model of brain-localized lung cancer metastasis. Entrectinib is currently showing great promise in phase I/II clinical trials, including the first documented objective responses to a TRK inhibitor in colorectal carcinoma and in NSCLC. The drug is, thus, potentially suited to the therapy of several molecularly defined cancer settings, especially that of TRK-dependent tumors, for which no approved drugs are currently available. Mol Cancer Ther; 15(4); 628–39. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-15-0758

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 321

Metadata

Authors
Ardini, E., Menichincheri, M., Banfi, P., Bosotti, R., De Ponti, C., Pulci, R., Ballinari, D., Ciomei, M., Texido, G., Degrassi, A., Avanzi, N., Amboldi, N., Saccardo, M. B., Casero, D., Orsini, P., Bandiera, T., Mologni, L., Anderson, D., Wei, G., Harris, J., Vernier, J.-M., Li, G., Felder, E., Donati, D., Isacchi, A., Pesenti, E., Magnaghi, P., & Galvani, A.
Venue
Molecular Cancer Therapeutics
Published
2016-04-01
Volume
15
Issue
4
Pages
628-639
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2292803562
Cited by
321
References
39
FWCI
25.69
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. https://app.cochat.ai/papers/10.1158/1535-7163.mct-15-0758
The paper
Ardini, E., Menichincheri, M., Banfi, P., Bosotti, R., De Ponti, C., Pulci, R., Ballinari, D., Ciomei, M., Texido, G., Degrassi, A., Avanzi, N., Amboldi, N., Saccardo, M. B., Casero, D., Orsini, P., Bandiera, T., Mologni, L., Anderson, D., Wei, G., . . . Galvani, A. (2016). Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-15-0758

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.